小剂量布地奈德联合多索茶碱治疗支气管哮喘的临床疗效及安全性分析

Analysis of clinical efficacy and safety of low-dose budesonide combined with doxofylline in the treatment of bronchial asthma

目的:探讨小剂量布地奈德联合多索茶碱治疗支气管哮喘的临床疗效及安全性分析。方法:收治支气管哮喘患者82例,随机分为两各组41例,对照组给予多索茶碱进行治疗,观察组在此基础上给予小剂量布地奈德进行治疗。评估两组临床疗效及不良反应。结果:观察组和对照组患者的临床总有效率分别为87.80%、41.46%,观察组临床总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组第1秒用力呼气容积(FEV_1)、肺活量(FVC)、呼气流速峰值(PEF)水平明显高于治疗组,差异有统计学意义(P<0.05)。结论:小剂量布地奈德联合多索茶碱治疗支气管患者的临床疗效确切,能有效改善肺功能指标且安全性高。

Objective:To investigate the clinical efficacy and safety of low dose budesonide combined with doxofylline in the treatment of bronchial asthma.Methods:82 patients with bronchial asthma were selected,they were randomly divided into the two groups with 41 cases in each group.Patients in the control group were treated with doxofylline,while patients in the observation group were treated with low dose budesonide on the basis of the control group.The clinical efficacy and adverse reactions of the two groups were evaluated.Results:The total clinical effective rate of the observation group and the control group were 90.00% and 42.00%,respectively.The total clinical effective rate of the observation group was significantly higher than that of the control group,with statistical significance(P<0.05).After treatment,the levels of FEV1,FVC and PEF in the observation group were significantly higher than those in the treatment group(P<0.05).Conclusion:Low-dose budesonide combined with doxofylline in the treatment of bronchial patients has definite clinical efficacy,which can effectively improve the lung function index and with high safety.